Directorate Change
Updated : 09:01
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Directorate Change
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that David Evans, Chairman of the Company, has resigned from the Board and stepped down with immediate effect.
Bill Rhodes has agreed to act as interim Chairman. Under David's leadership, the Company had already been in the process of identifying and recruiting an additional Non-Executive Director to further strengthen the Board. During that process, David decided that after 18 years' service, the opportunity to also bring fresh perspective from the position of Chairman would enable the Board to focus on the reshaped business and new opportunities that lie ahead.
Colin King, Chief Executive of Omega Diagnostics, commented: "The Board would like to thank David for his invaluable contribution during his 18 years of service and wish him all the best for the future."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | |
Kieron Harbinson, Group Finance Director | |
Mob: 07740 084452 | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/James Thompson (Corporate Finance) | |
Camille Gochez (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.